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Abstract
Background There is a high prevalence of liver injury (LI) in patients with coronavirus disease 2019 (COVID-19); however,
few large-scale studies assessing risk factors and clinical outcomes in these patients have been done.
Aims To evaluate the risk factors and clinical outcomes associated with LI in a large inpatient cohort of COVID-19 patients.
Methods Adult patients with COVID-19 between March 1 and April 30, 2020, were included. LI was defined as peak levels
of alanine aminotransferase/aspartate aminotransferase that were 3 times the ULN or peak levels in alkaline phosphatase/
total bilirubin that were 2 times the ULN. Mild elevation in liver enzymes (MEL) was defined as abnormal peak liver enzyme
levels lower than the threshold for LI. Patients with MEL and LI were compared to a control group comprising patients with
normal liver enzymes throughout hospitalization.
Results Of 1935 hospitalized COVID-19 patients, 1031 (53.2%) had MEL and 396 (20.5%) had LI. Compared to control
patients, MEL and LI groups contained proportionately more men. Patients in the MEL cohort were older compared to
control, and African-Americans were more highly represented in the LI group. Patients with LI had an increased risk of
mortality (relative risk [RR] 4.26), intensive care unit admission (RR, 5.52), intubation (RR, 11.01), 30-day readmission
(RR, 1.81), length of hospitalization, and intensive care unit stay (10.49 and 10.06 days, respectively) compared to control.
Conclusion Our study showed that patients with COVID-19 who presented with LI had a significantly increased risk of
mortality and poor clinical outcomes.
Keywords COVID-19 · SARS-CoV-2 · Liver injury · Risk factors · Clinical outcomes

Introduction
Coronaviruses are a family of viruses that cause respiratory and intestinal illness in humans [1]. These viruses can
affect the upper respiratory tract, manifesting as diseases
like the common cold, or in more extreme cases, pneumonia [2]. Severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) is the virus that causes the coronavirus
disease 2019 (COVID-19). The first cases of COVID-19
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emerged in December 2019 in the city of Wuhan in the Chinese province of Hubei, where most patients presented with
viral pneumonia. Since then, COVID-19 has spread globally
and is recognized as a global pandemic by the World Health
Organization [3].
Recent studies have shown that COVID-19 can affect
multiple organs, and more than half of patients with COVID19 can have varying levels of liver enzyme abnormalities
[4]. Some reports have shown that the liver is the most frequently involved organ outside of the respiratory system
[5–7]. According to one study, the SARS-CoV-2 virus may
bind to angiotensin-converting enzyme 2 (ACE2) on cholangiocytes, resulting in cholangiocyte dysfunction and hence
inducing a systemic inflammatory response that can lead to
liver injury (LI) [8].
Although there has been a fair amount of recent research
on liver enzyme abnormalities and associated clinical
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characteristics among patients with COVID-19, most of
these studies have been relatively small and were not conducted on a US population. Also, only a few studies focused
specifically on hospital-based outcomes. In this study, our
objective was to determine the risk factors and clinical outcomes associated with LI in a large cohort of patients who
were hospitalized with COVID-19.

phosphatase 140 IU/L were used. These threshold values
were defined by the health system’s laboratory experts.
Two cohorts, patients with MEL and patients with LI, were
compared with a control group that comprised COVID-19
patients with normal LFTs at presentation and throughout
hospitalization. Primary outcomes were 60-day mortality,
intensive care unit (ICU) admission, intubation, 30-day readmission, length of hospitalization and length of ICU stay.

Methods

Statistical Analysis

Study Design

All continuous data were reported as means and standard
deviations, while categorical data were reported as counts
and column percentages. For continuous variables, univariate two-group comparisons were performed using one-way
analysis of variance tests if the variable was normally distributed and Kruskal–Wallis tests if the variable was not
normally distributed. For categorical variables, univariate
two-group comparisons were made using Chi-square tests
when expected cell counts were > 5 and Fisher’s exact tests
when expected cell counts were < 5. Relative risk (RR) for
the outcomes of interest was assessed using the log-binomial method. Pairwise post hoc tests were performed using
a Bonferroni adjustment. To compare patients with cirrhosis,
chronic liver disease, and those without chronic liver disease, generalized linear mixed modeling was used to account
for the fact that these groups were not mutually exclusive. A
Tukey–Kramer adjustment was used for multiple comparisons. For binary outcome variables, statistical significance
was set at P < 0.05. All analyses were performed using SAS
9.4 (SAS Institute Inc., Cary, NC).

This study was approved by the Henry Ford Health System
Institutional Review Board. This study was a retrospective
medical record review at a large tertiary care health system
in Detroit, Michigan. Patients with SARS-CoV-2 infection
confirmed by positive polymerase chain reaction testing of
a nasopharyngeal specimen were included. The study cohort
consisted of patients who were admitted and discharged to
any of the five hospitals within the Henry Ford Health System between March 1 and April 30, 2020. Patients who were
discharged directly from the emergency department or evaluated in outpatient clinics were not included. If patients were
admitted multiple times during the study interval, only the
index admission following a positive COVID-19 test result
was considered.

Data Collection
A team of physicians performed a manual retrospective chart
review on a standardized data collection form using the electronic medical record. Demographic data were collected
including sex, age, race, body mass index, and current or
prior cigarette use. The presence of baseline medical comorbidities including diabetes, sleep apnea, chronic obstructive
pulmonary disease, asthma, hypertension, cardiovascular
disease, and malignancy was recorded. Cardiovascular disease was defined by the presence of coronary artery disease, prior myocardial infarction, cerebrovascular disease,
congestive heart failure, cardiac arrhythmia, or congenital
heart disease.
Patients’ peak liver enzymes during the index admission
were also collected. Mild elevation in liver enzymes (MEL)
was defined as peak levels of alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase, and total
bilirubin above the upper limit of normal (ULN) levels but
lower than the threshold level for LI. LI was defined as peak
levels of alanine aminotransferase/aspartate aminotransferase 3 times the ULN level or peak alkaline phosphatase/
total bilirubin levels 2 times the ULN level. ULN threshold
values of alanine aminotransferase 52 IU/L, aspartate aminotransferase 35 IU/L, total bilirubin 1.2 mg/dL, alkaline
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Results
Characteristics of Patients with COVID‑19
with Elevated Liver Enzyme Levels
A total of 1935 patients who tested positive for COVID-19
and were hospitalized between March 1 and April 30, 2020,
were included in the study. Of the 1935 patients 972 were
men (50.2%) and 963 were women (49.8%), with a mean
(standard deviation) age of 61.7 (17) years. Five hundred and
eight patients (26.2%) with normal liver enzymes (control
group), 1031 patients (53.2%) with MEL, and 396 patients
(20.5%) with LI. Men were more common in the MEL
group (50%; P = 0.0006) and LI groups (64%; P < 0.0001)
compared to the control group of patients with normal liver
enzymes (40%) (Table 1).
Although patients in the MEL cohort were on average
older compared to controls (65.1 vs. 61.7 years; P = 0.0010),
the difference in age between the LI cohort and control
group was not significant (63.4 vs. 61.7 years; P = 0.4270).

Digestive Diseases and Sciences
Table 1  Comparison of patient clinical characteristics (MEL vs. control and LI vs. control) (N = 1935)
Variable
Sex, N (%)
Female
Male
Age, years, mean (SD)
Race/ethnicity, N (%)
Black
White
Asian
Hispanic
Other
BMI, kg/m2, mean (SD)
Comorbidities, N (%)
Diabetes
Sleep apnea
Hypertension
Cardiovascular disease
Malignancy
Chronic liver disease
CRP mg/dL (peak), mean (SD)
Ferritin ng/mL (peak), mean (SD)

a

MEL (n = 1031)

LI (n = 396)

304 (60%)
204 (40%)
61.7 (17.7)

516 (50%)
515 (50%)
65.1 (15.7)

143 (36%)
253 (64%)
63.4 (15.9)

278 (56%)
178 (36%)
8 (2%)
2 (0%)
28 (6%)
31.6 (9.2)

569 (58%)
341 (35%)
16 (2%)
4 (0%)
50 (5%)
31.6 (8.5)

238 (64%)
106 (29%)
15 (4%)
1 (0%)
13 (3%)
31.7 (8.6)

206 (41%)
53 (10%)
333 (66%)
146 (29%)
32 (6%)
14 (3%)
9.5 (7.8)
586.1 (782.3)

387 (38%)
105 (10%)
711 (69%)
288 (28%)
73 (7%)
41 (4%)
13.7 (8.9)
1144.9 (1855.9)

153 (39%)
35 (9%)
271 (68%)
125 (31%)
37 (9%)
11 (3%)
18.5 (10.7)
3388.7 (7501.1)

Control (n = 508)

Overall bP value

Control versus
MEL bP value

Control versus
LI bP value

< 0.0001

0.0006

< 0.0001

0.0006
0.0319

0.0010
1.000

0.4270
0.0260

0.9796

1.000

1.000

0.5062
1.000
0.3558
1.000
1.000
0.4502
< 0.0001
0.0352

1.000
0.8446
0.7220
0.7152
0.1744
1.000
< 0.0001
< 0.0001

0.5202
0.6896
0.3926
0.4030
0.1984
0.3443
< 0.0001
< 0.0001

BMI, body mass index; CRP, C-reactive protein; LI, liver injury; MEL, mild elevation in liver enzymes; SD, standard deviation

a

b

Control patients had all liver enzymes within reference range

P values reported using one-way analysis of variance test for age and BMI and Chi-square test or Fisher’s exact test for other patient characteristics

African-Americans were more highly represented in the LI
group (58%; P = 0.0260). Between all 3 groups, there was
no difference in patient comorbidities including body mass
index, diabetes, sleep apnea, hypertension, cardiovascular
disease, and malignancy (Table 1).

elevation. Mean C-reactive protein was 9.5 mg/dL in the
control cohort, 13.7 mg/dL in the MEL cohort, and 18.5 mg/
dL in the LI cohort (P < 0.0001). Similarly, mean ferritin
was 586 ng/mL in the control cohort, 1145 ng/mL in the
MEL cohort, and 3389 ng/mL in the LI cohort (Table 1).

Laboratory Parameters of Patients with COVID‑19
with Elevated Liver Enzyme Levels

Clinical Outcomes

Among patients with LI, 241 (61%) had a hepatocellular pattern, 20 (5%) had a cholestatic pattern, and 135 (34%) had a
mixed pattern. Of the 1031 patients with MEL, the median
alanine aminotransferase was 39 IU/L (range 5–156), the
median aspartate aminotransferase was 52 IU/L (range
15–105), the median alkaline phosphatase was 71 IU/L
(range 24–258), and the median total bilirubin was 0.8 mg/
dL (range 0.2–2.4). Of the 396 patients with LI, the median
alanine aminotransferase was 131.5 IU/L (range 3–8518),
the median aspartate aminotransferase was 141.5 IU/L
(range 13–19,689), the median alkaline phosphatase was
97.5 IU/L (range 36–830), and the median total bilirubin
was 1 mg/dL (range 0.2–22.7). Elevation in C-reactive protein and ferritin was correlated with severity of liver enzyme

Patients with LI had an increased risk of mortality (RR,
4.26; 95% CI 3.12–5.81; P < 0.0001), ICU admission (RR,
5.52; 95% CI 4.07- 7.49; P < 0.0001), intubation (RR, 11.01;
95% CI 6.97–17.34; P < 0.0001), and 30-day readmission
(RR, 1.81; 95% CI 1.17–2.80; P < 0.0076) compared to the
controls. Although patients with MEL had an increased
risk of mortality (RR, 2.16; 95% CI 1.59–2.95; P < 0.0001),
ICU admission (RR, 2.48; 95% CI 1.82–3.37; P < 0.0001),
and intubation (RR,3.76; 95% CI 2.36–5.99; P < 0.0001)
compared to the control group, there was no significant difference in the risk of 30-day readmission (RR,1.25; 95%
CI 0.86–1.82; P = 0.2415) (Table 2). Compared to the control group, patients with LI had a fourfold higher rate of
mortality, fivefold higher rate of ICU admissions, 11-fold
higher rate of intubation, and twofold higher rate of 30-day
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Table 2  Relative risks’ main
outcomes in patients with MEL
or LI compared to control

Outcome

Mildly elevated liver enzymes versus
control
Relative risk (95% CI)

60-day mortality
ICU admission
Intubation
30-day readmission

2.16 (1.59–2.95)
2.5 (1.8–3.4)
3.76 (2.36–5.99)
1.25 (0.86–1.82)

a

Liver injury versus control

P value

Relative risk (95% CI)

< 0.0001
< 0.0001
< 0.0001
0.2415

4.26 (3.12–5.81)
5.52 (4.07–7.49)
11.01 (6.97–17.34)
1.81 (1.17–2.80)

a

P value
< 0.0001
< 0.0001
< 0.0001
0.0076

ICU, intensive care unit; LI, liver injury; MEL, mild elevation in liver enzymes; RR, relative risk

a

P values reported using Chi-square test

readmissions (Fig. 1). Moreover, patients with LI and MEL
had a longer length of hospitalization (10.5 days, P < 0.0001
and 7.6 days, P < 0.0001) and ICU stay (10.1 days,
P < 0.0001 and 8.1 days, P < 0.0154) compared to control.
Among the patients in our study, 66 (3.4%) had previously been diagnosed with chronic liver disease, 18 of
whom had cirrhosis. The cause of the underlying liver disease was mainly related to Hepatitis C and NAFLD/NASH,
which together comprised 73% of this cohort (57.5% and
15%, respectively). Fourteen of these patients did not have
elevated liver enzymes during their hospitalization, two of

whom were previously diagnosed with cirrhosis. Patients
with cirrhosis had a higher mortality rate (RR, 2.19; 95%
CI 1.33–3.62; P = 0.0022) compared to controls, while
patients with chronic liver disease without preexisting cirrhosis did not have a significantly different mortality rate
(RR, 1.40; 95% CI 0.93–2.09; P = 0.1062). Patients with
chronic liver disease both with and without preexisting cirrhosis showed no significant difference in ICU admissions,
intubation, and 30-day readmissions compared to patients
without chronic liver disease (Table 3).

Fig. 1  Incidence of adverse outcomes in patients with MEL and LI versus control. Abbreviations: ICU, intensive care unit; LI, liver injury;
MEL, mild elevation in liver enzymes
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Table 3  Morbidity and mortality associated with cirrhosis and chronic liver disease without cirrhosis
Outcome

Cirrhosis
Chronic liver
disease without
cirrhosis

Relative risk (95% CI; aP value)
Death

ICU admission

Intubation

30-Day readmission

2.19 (1.33–3.62; P = 0.0022)
1.40 (0.93–2.09; P = 0.1062)

0.41 (0.11–1.55; P = 0.1887)
1.06 (0.69–1.63; P = 0.7991)

0.28 (0.04–1.90; P = 0.1922)
1.17 (0.71–1.92; P = 0.5323)

2.35 (0.86–6.42; P = 0.0950)
1.24 (0.58–2.67; P = 0.5779)

ICU, intensive care unit
a

P values reported using log-binomial method

Discussion
In this study, we observed that patients with MEL or LI
had significantly higher intubation rates, ICU admission,
mortality, length of hospitalization, and length of ICU stay
compared to a control cohort of patients with normal liver
enzymes. To our knowledge, this is the largest single-center
retrospective study evaluating the relationship between liver
enzyme elevation and COVID-19 severity in an inpatient
cohort. Our study included patients who were hospitalized
across multiple medical facilities within the larger Detroit
metropolitan area, a region that was heavily affected by the
COVID-19 pandemic. Our patient population was notably
unique compared to other studies in that it had a significant
proportion of African-Americans, who have been shown to
be disproportionately affected by COVID-19 [9–11]. While
African-Americans comprise 14% of the population in the
state of Michigan, the city of Detroit has a large proportion
of African-Americans, where 79% of citizens are black [12].
In our study, African-Americans made up 56% of the study
population and were also significantly more likely to have
LI than patients of other races.
Our study aligns with current research that has shown
that hepatic injury is common in COVID-19 infection and
related to disease severity. Liver enzymes elevation was
noted in 73.7% of our study group, where the rate of MEL
was 53.2% and more severe LI was 20.5%. Although the rate
of liver enzyme elevation reported in our study was much
higher than the 28.2% reported by Hao et al., it was more
consistent with the 72.4% rate reported by Phipps et al. [13,
14]. Patients with MEL or LI had higher levels of systemic
inflammation. The mean C-reactive protein in patients with
MEL was 13.7 mg/dL and for patients with LI was 18.5 mg/
dL. Ferritin was also significantly higher with a mean of
1144 ng/mL in MEL and 3388 ng/mL in LI. The pattern of
LI that we observed was similar to findings in other studies
that reported elevated aspartate aminotransferase and alanine
aminotransferase in severe disease [15]. Of the patients in
our study, 61% developed hepatocellular injury, followed
by a mixed pattern in 34% and a cholestatic pattern in only
5%. Of unclear significance is the finding that male patients

were more highly represented in both MEL and LI cohorts
and that African-Americans were more likely to have LI
than other races. Further studies will need to be done to
corroborate these associations and find a causal relationship;
however, the associations that we identified will help in risk
stratification of a patient’s disease severity. Other comorbidities including diabetes, sleep apnea, chronic obstructive
pulmonary disease, asthma, hypertension, cardiovascular
disease, and malignancy did not seem to be associated with
these outcomes either.
The impact of chronic liver disease on the severity of
COVID-19 was also evaluated in our study. The prevalence
of underlying liver disease was 3.4%, with almost a third
of these patients having cirrhosis. Fourteen of those with
chronic liver disease did not have elevation in their liver
enzymes during their COVID-19 hospitalization. Two of
these patients had underlying cirrhosis, and ten had HCV
as their underlying disease process. The lack of elevations
in these patients is curious, but can possibly be attributed to
control of their underlying disease. Our study did not distinguish between HCV Ab-positive patients and NAT positive,
and it is possible that those patients without elevations had
been previously treated for their Hepatitis C. Further studies are required to delineate this relationship. Overall, our
study showed that although cirrhosis conferred an increased
risk of mortality related to controls, chronic liver disease
without cirrhosis did not have an increased mortality rate
and furthermore did not have higher rates of ICU admission, intubation, or 30-day readmission risk. These findings
are in line with recent published data. The meta-analysis
performed by Kovalic et al. found underlying chronic liver
disease in 3% of patients with COVID-19 infection [16].
These patients, which included those with cirrhosis, had an
increased incidence of overall mortality as well as severe
COVID-19 infection. Kim et al. performed a large US multicenter study looking specifically at patients with chronic
liver disease and COVID-19 [17]. They showed an all-cause
mortality of 14% with risk factors for increased mortality
being alcohol-related liver disease, decompensated cirrhosis, and hepatocellular carcinoma. Our study population has
some differences when compared to these studies; however,
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it reinforces the growing fund of knowledge that cirrhosis
can confer an increased mortality risk and that this vulnerable population should take extra precaution to safeguard
against contracting COVID-19.
The pathogenesis of LI in COVID-19 is still under
investigation. However, it is thought to be related to one of
three processes: direct viral infection of the liver, hepatic
inflammation from activation of the innate immune system,
or drug-induced LI. During the SARS-CoV epidemic that
occurred in 2003, it was noted that up to 66% of patients
had elevated liver enzymes [18]. With that virus, which has
82% homology with SARS-CoV-2, there was evidence of
direct LI with autopsy studies showing detectable virus in
41% of liver tissue and overexpression of a viral-encoded
protein shown to induce apoptosis in liver cells [19–21]. In
addition to significant genomic homology, the SARS-CoV-2
virus also has a similar mechanism of infection as its earlier
counterpart, which is via the ACE2 receptor [18]. Although
not highly expressed on hepatocytes, ACE2 has significant
expression on cholangiocytes [8], and one role of these cells
is an adaptive immune response mechanism in the liver, disruption of which could lead to hepatic damage [22]. Sterile
inflammation has long been known to cause hepatic injury,
as evidenced by disease processes such as autoimmune
hepatitis and primary sclerosing cholangitis. The SARSCoV-2 virus has been showed to substantially elevate proinflammatory cytokines leading to a cytokine storm, manifested as elevated inflammatory markers with lymphopenia
from reduction of T cells and NK cells [23]. Earlier studies
have shown that these markers (e.g., elevated C-reactive
protein ≥ 20 mg/L and lymphopenia < 1.1 × 10^9/L) were
independent risk factors for hepatic injury [24]. Finally,
drug-induced LI is another likely etiology of some LI in
COVID-19. The medication most implicated is lopinavir–ritonavir, where one case series reported that 55.4% of
patients experienced LI after treatment [25]. So far, liver
biopsy has not yielded a clear etiology. One reported biopsy
from a COVID-19 patient autopsy showed nonspecific LI
findings including moderate microvesicular steatosis and
mild inflammation in the lobular portal region [26].
This study has several limitations. First, it may not be
generalizable, since our data were collected from a single
large health system, and the demographics of the patient
cohort may not be reflective of the general population. Second, the resources available at a tertiary care facility such
as ours are not readily available at many non-tertiary care
centers, and this may have affected patient outcomes. Third,
we only evaluated patients who required hospital admission
and, therefore, were unable to capture the large proportion of
patients who were cared for in the outpatient setting or were
discharged home from the emergency department. Finally, as
with any retrospective study, results may be subject to confounding bias from unknown variables. Two such variables
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are medication administration between the groups, which
could have affected liver enzyme elevation, and lack of availability of baseline liver enzymes to serve as a reference point
for MEL and LI, which again could confound the results. We
recognize that using peak elevation of liver enzymes cannot
indicate the timing of patient LI in relation to COVID-19
(i.e., whether the patient had an underlying liver condition, developed LI from drug toxicity, or developed LI as a
sequela of viral infection). However, we propose that regardless of the timing or source of LI in COVID-19 patients, the
presence of LI during a COVID-19 hospitalization may be
indicative of the possibility of a severe outcome, highlighting LI as a bellwether of an unfavorable disease trajectory.
Notably, we used similar ULN cutoffs for both men and
women for parsimony, although a finer analysis would take
gender-specific trends into consideration. Some of our ULN
cutoffs may be different from those at other institutions, and
this may have skewed our findings.
As of July 30, 2020, the World Health Organization
reported over 16.8 million confirmed COVID-19 cases
worldwide [27]. This global pandemic has caused significant morbidity and mortality, with over 662,095 deaths and
untold economic damage. As of now, treatment is mainly
supportive with consideration of anti-inflammatory agents,
immunomodulatory therapies, certain antivirals, and antibody therapy such as convalescent plasma. Until a vaccine is
developed and clinical trials on treatments yield more established and convincing treatment algorithms, prognostication
of patients is critical.

Conclusion
In summary, we reported that patients with MEL or LI
developed more severe disease and had increased intubation
rates, ICU admission, mortality, length of hospitalization,
and length of ICU stay as well increased 30-day readmission
for patients with LI. This information is critical for optimal clinical decision making, and liver enzymes should be
routinely monitored to allow for risk stratification and early
treatment decisions. Further research looking at risk prediction models and pooling multicenter data should include LI
as a key variable.
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